ArticleJournal of translational medicine2026

MSDC-0160, a novel clinical-stage mitochondrial pyruvate carrier inhibitor, suppresses osteoclast differentiation and alleviates type 2 diabetes-related bone loss.

Chaofeng Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.